A Phase 1 interventional study of LY3502970 in Renal Insufficiency and Healthy, sponsored by Eli Lilly and Company. Completed at 4 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-09.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Renal Insufficiency by Eli Lilly and Company — 1 open to participants now, 2 under way, none of them phase 3. Renal Insufficiency · Eli Lilly and Company.
Among the 12 studies in Renal Insufficiency by Eli Lilly and Company, this one is the 10th largest by enrollment, is one of 3 that started in 2023, is one of 12 in phase 1, and was the 7th registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.
Browse Renal Insufficiency studies →1 of the 12 studies in Renal Insufficiency by Eli Lilly and Company is open now, in 1 country. Recruiting first, the newest first:
Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company · Sites in United States
Ages 18–85 · Healthy volunteers
By country, each count listing its studies:
Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 40 across 1,060 interventional studies indexed under Renal Insufficiency.
Median enrollment 30 across the 12 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
1 of the studies in Renal Insufficiency by Eli Lilly and Company that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07924930Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and CompanyA Study of Tersolisib (LY4064809) in Participants With Kidney Impairment Compared With Participants With Normal Kidney Function | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Renal Insufficiency by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to assess the amount of study drug (LY3502970) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to participants with normal renal function. The safety and tolerability of LY3502970 will also be evaluated in these participants. The study will last up to 6 weeks including screening period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with Normal Renal Function:
Participants with Renal Impairment:
Exclusion Criteria:
Participants with Renal Impairment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single oral dose of 1 milligram (mg) LY3502970 was administered to participants with normal renal function \[defined as an estimated glomerular filtration rate (eGFR: ≥ 90 milliliters per minute (mL/min), and without a diagnosis of type 2 diabetes mellitus (T2D)\] on day 1.
Drug: LY3502970
A single oral dose of 1 mg LY3502970 was administered to participants with severe renal function \[defined as an eGFR: 15-29 mL/min and not requiring hemodialysis, with a diagnosis of T2D\] on day 1.
Drug: LY3502970
A single oral dose of 1 mg LY3502970 was administered to participants with end stage renal disease \[defined as an eGFR: less than 15 mL/min or requiring hemodialysis, with a diagnosis of T2D\] on day 1.
Drug: LY3502970
Administered orally.
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-∞) of LY3502970
PK: (AUC0-∞) of LY3502970 is reported.
Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours postdose
PK: Area Under the Concentration Versus Time Curve From Time Zero to Last Time Point (AUC0-tlast) of LY3502970
PK: AUC0-tlast of LY3502970 is reported.
Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours postdose
PK: Maximum Observed Concentration (Cmax) of LY3502970
PK: Cmax of LY3502970 is reported.
Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours postdose
| Milestone | LY3502970 (Normal Renal Function) | LY3502970 (Severe Renal Impairment) | LY3502970 (End-Stage Renal Disease) |
|---|---|---|---|
| Started | 10 | 6 | 8 |
| Completed | 9 | 6 | 7 |
| Not completed | 1 | 0 | 1 |
| Withdrew: Inadvertent enrollment | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
PK: (AUC0-∞) of LY3502970 is reported.
| nanogram*hour per milliliter (ng*hr/mL) | LY3502970 (Normal Renal Function) | LY3502970 (Severe Renal Impairment) | LY3502970 (End-Stage Renal Disease) |
|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-∞) of LY3502970 | 113 ± 32.1 | 167 ± 48.6 | 108 ± 87.8 |
PK: AUC0-tlast of LY3502970 is reported.
| ng*hr/mL | LY3502970 (Normal Renal Function) | LY3502970 (Severe Renal Impairment) | LY3502970 (End-Stage Renal Disease) |
|---|---|---|---|
| PK: Area Under the Concentration Versus Time Curve From Time Zero to Last Time Point (AUC0-tlast) of LY3502970 | 98.9 ± 32.9 | 120 ± 48.9 | 90.2 ± 79.7 |
PK: Cmax of LY3502970 is reported.
| nanogram per millilitre (ng/mL) | LY3502970 (Normal Renal Function) | LY3502970 (Severe Renal Impairment) | LY3502970 (End-Stage Renal Disease) |
|---|---|---|---|
| PK: Maximum Observed Concentration (Cmax) of LY3502970 | 5.01 ± 20.7 | 6.01 ± 54.9 | 4.29 ± 67.3 |
Collected over Baseline through follow-up (Up to 12 Days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LY3502970 (Normal Renal Function) | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| LY3502970 (Severe Renal Impairment) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| LY3502970 (End-Stage Renal Disease) | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| Event | LY3502970 (Normal Renal Function) | LY3502970 (Severe Renal Impairment) | LY3502970 (End-Stage Renal Disease) |
|---|---|---|---|
| HaemodialysisSurgical and medical procedures | 0/10 | 0/6 | 5/8 |
| NauseaGastrointestinal disorders | 0/10 | 1/6 | 1/8 |
| VomitingGastrointestinal disorders | 0/10 | 1/6 | 1/8 |
| Amylase increasedInvestigations | 0/10 | 1/6 | 0/8 |
| Lipase increasedInvestigations | 0/10 | 1/6 | 0/8 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/10 | 1/6 | 0/8 |
| DiarrhoeaGastrointestinal disorders | 0/10 | 0/6 | 1/8 |
All enrolled participants.
| Age, Continuous(years) | LY3502970 (Normal Renal Function) | LY3502970 (Severe Renal Impairment) | LY3502970 (End-Stage Renal Disease) | Total |
|---|---|---|---|---|
| Mean | 58.6 ± 6.54 | 61.7 ± 17.07 | 53.8 ± 10.42 | 57.8 ± 11.09 |
| Sex: Female, Male(Participants) | LY3502970 (Normal Renal Function) | LY3502970 (Severe Renal Impairment) | LY3502970 (End-Stage Renal Disease) | Total |
|---|---|---|---|---|
| Female | 2 | 2 | 0 | 4 |
| Male | 8 | 4 | 8 | 20 |
| Ethnicity (NIH/OMB)(Participants) | LY3502970 (Normal Renal Function) | LY3502970 (Severe Renal Impairment) | LY3502970 (End-Stage Renal Disease) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 1 | 3 | 7 |
| Not Hispanic or Latino | 7 | 5 | 4 | 16 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | LY3502970 (Normal Renal Function) | LY3502970 (Severe Renal Impairment) | LY3502970 (End-Stage Renal Disease) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 4 | 8 |
| White | 7 | 5 | 3 | 15 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
| Region of Enrollment(Participants) | LY3502970 (Normal Renal Function) | LY3502970 (Severe Renal Impairment) | LY3502970 (End-Stage Renal Disease) | Total |
|---|---|---|---|---|
| United States | 10 | 6 | 8 | 24 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2023 to primary completion in Apr 2024, 8 months.
Results were first posted in Jun 2026, 2 years 1 month after primary completion.
Of 212 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 8 months is close to that.
Counting every sponsor, half of 230 studies reached it within 8 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron